Company news

Kodiak Sciences Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

October 10, 2023

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 7, 2023

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

September 6, 2023

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

August 13, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

July 23, 2023

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

May 14, 2023

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

April 20, 2023

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

April 2, 2023

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

March 27, 2023

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

February 8, 2023

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

November 15, 2022

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

November 8, 2022

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

September 6, 2022

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

August 17, 2022

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

August 8, 2022

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

August 7, 2022

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

August 4, 2022

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference

May 26, 2022

Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases

May 18, 2022

Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights

May 9, 2022

Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences

April 28, 2022

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

February 28, 2022

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

February 22, 2022

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

February 2, 2022

Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

December 15, 2021

Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights

November 8, 2021

Kodiak Sciences to Present at Upcoming Conferences

November 7, 2021

Kodiak Sciences Announces New Long-Term Performance Incentive Plan

August 31, 2021

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

August 30, 2021

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

August 8, 2021

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

May 9, 2021

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

February 28, 2021

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

February 1, 2021

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

January 4, 2021

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

November 19, 2020

Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

November 16, 2020

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

November 15, 2020

Kodiak Sciences Announces Proposed Offering of Common Stock

November 15, 2020

Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting

November 10, 2020

Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights

November 8, 2020

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

October 28, 2020

Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

October 4, 2020

Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights

August 9, 2020

Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress

July 15, 2020

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar

July 6, 2020

Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

May 10, 2020

Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

May 10, 2020

Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020

May 7, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 40 decks. Every deck is listed under its year.